Pulmatrix, Inc. (NASDAQ:PULM)‘s shares have oscillated between a high of $-60.32% and a low of $451.79% over the last 12 months.
For the last 50 days, the stock has risen to a peak price of $-39.65% and hit a bottom of $23.11%.
The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum. The market is approaching oversold territory. Be watchful of a trend reversal.
Recently, Pulmatrix, Inc. (NASDAQ:PULM) announced that it received a key U.S. patent for its lead drug candidate PUR0200, a treatment for chronic obstructive pulmonary diseases (COPD). “This patent ensures that the product is protected by intellectual property until 2033,” said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. “It also is further recognition of the potential medical advances offered by our innovative iSPERSE™ technology for delivering drugs to the lungs more efficiently.”
On moving volumes measurements, the stock’s 20-Day Simple Moving Average price is $1.51%, 50-Day Simple Moving Average is $-8.02% and 200-Day Simple Moving Average is $34.61%.
The stock is now moved 369.49% for the year. Over the last six months it has moved 204.40%, compared with a movement of -32.60% for the quarter, -2.81%% for the month and 4.92% for the week.
The average volume, usually a measurement of three months average, is 2.00M. Relative volume on the other hand is 2.84. In total, Pulmatrix, Inc. has 19.28M shares outstanding, with 18.40M of them being free float shares.
The stock?s short float stands at 8.63%, working out to a short ratio of 0.79.
Institutional investors own 34.10% of Pulmatrix, Inc.?s equity, while insiders own 26.44% of the stock. In the last couple of months, the stock has seen -12.31% institutional investor transactions, compared to 0.00% insider transactions.
How have the investors seen their investment in the stock change? Pulmatrix, Inc.’s return on equity for the trailing 12 months is -164.80% and return on investments for a similar period calculates to -184.50%. The company posted return on assets of -109.50% for the same trailing 12 months period.
Does Pulmatrix, Inc. have the ability to keep its doors open ? at least over the short-term? The company’s current ratio at the end of the most recent quarter was 2.50, while quick ratio for the same period was 2.50.
For the matters of debt, the company’s Long Term Debt/Equity for the most recent quarter was 0.16 and Total Debt/Equity for the same period was 0.33.